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have been made to grow these tumors in vitro.
successful adaptation to primary cultures was onlyachieved either in thepresence
offeeder cells (4, 5) or after repeated passage between culture and mouse (2, 6-
8). For some plasmacytomas, feeder cells could be replaced by soluble factors
secreted by macrophages (3, 4, 9), Tlymphocytes (10), or a variety ofother cells
(4). However, so far, none of these factors has been clearly identified.
We have recently describedaTcell-derived factor thatwasabsolutely required
far the in vitro growth of certain B cell hybridoma lines and appeared to be
distinct from interleukin 1 (IL-1), IL-2, IL-3, interferon y (IFN-'Y), B cell-
stimulatory factor I (BSF-1),' and B cell-growth factor 11. This factor was
produced in high titers by a C57BLJ6 helper T cell clone upon stimulation with
a clonotypic antibody. After purification by sequential gel filtration,
exchange,andreversed-phase high performanceliquid chromatography (HPLC),
the growth factor appeared to copurify with a single chain glycoprotein that was
very heterogeneous both in charge (pI 5-7) and molecular mass (22-29 kD in
SDS polyacrylamide gels). Sequencing of this material generated a single NH2-
terminal amino acid sequence that clearly identified this factor as a new lympho-
kine, which we provisionally designated interleukin-HP1 (IL-HPI) (11).
In thepresent report, we show that IL-HP1 acts not onlyon Bcell hybridomas,
but is also a major growth factor for many murine plasmacytomas.
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Materials and Methods
Plasmacytoma Cultures.
￿
Plasmacytomas originally obtained from Dr. Michael
er (National Institutes of Health, Bethesda, MD) were maintained as ascitic tumors in
pristane-treated BALE/c mice (12). The animals were irradiated with 500 rad from a
cesium source just before tumor transplantation. After 7-10 d, the peritoneal cavi
the mice was flushed with 5 ml Iscove's medium containing heparin (50 U/tnl) and JO%
FCS. Nucleated cells, separated from erythrocytes by centrifugation on Ficoll-Paque
(Pharmacia Fine Chemicals, Uppsala, Sweden), were seeded in 24-well plates at 2.5-5 x
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' Abbreviation used in this paper:
￿
BSF, B cell-stimulatory factor.
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105 cells/ml in Iscove's medium supplemented with 10% FCS, 2-ME (50 AM), L-arginine
(0.55 MM), L-asparagine (0.24 mM), and L-glutamine (1 .5 mM). Medium was changed
every other day, and cell concentrations were maintained at 1-5 X 105 cells/ml . Factor-
dependent plasmacytoma and hybridoma cell lines were maintained in the same medium
supplemented with appropriate concentrations of T cell supernatant (usually 2% for
plasmacytomas and 0.01 % for hybridomas).
Preparation of TUC2.15 Supernatant.
￿
Helper T cell clone TUC2.15 was derived from
C57BL/6 mice immunized with keyhole limpet hemocyanin (KLH). For mass production
of this clone, 5 X 106 T cells were cultured with 2 X 108 syngeneic spleen cells (irradiated
with 2,000 rad from a cesium source) in 50 ml Dulbecco's modified Eagle's medium
containing 25 Ag/ml KLH and supplemented with amino acids, 2-ME, and FCS as
described above for plasmacytoma cells. After 10-15 d, these cultures yielded 4.0-5 .0 X
10' TUC2.15 cells. For the preparation of TUC2.15 supernatant, 10-d-old cultures were
washed in medium without serum and the cells were incubated for 3-4 d with clonotypic
monoclonal antibody 3D7 in medium with a low protein concentration (0.5% FCS or 10
ug/ml human transferrin). The 3D7 antibody, which was derived from 129/Sv mice
immunized with TUC2 .15, stimulated lymphokine secretory activity and proliferation of
TUC2.15, but of no other helper T cell clones. It was used here as a 10,000-fold diluted
ascites.
Biochemical Procedures.
￿
Crude TUC2.15 supernatant was concentrated by adsorption
on silicic acid (3 g/liter for 3 h at 4° C) and elution with 50% ethylene glycol and 50% 1 .4
M NaCl containing 12 mM phosphate buffer, pH 7.2. Aliquots of this material were
analyzed by gel filtration, isoelectric focusing, or reversed-phase HPLC. Gel filtration was
carried out on an Ultrogel AcA 54 column (LKB, Bromma, Sweden) equilibrated with
18% ethylene glycol in 1 M NaCl containing 12 mM phosphate buffer pH 7.2. For
isoelectric focusing, samples were applied to a prefocused (600 V for 1 h) flat-bed
polyacrylamide (5%) gel equilibrated with pH 3.5-10ampholines (2.5%, LKB) and focused
for 2 h at 1,000 V. Material eluted from the gel was tested for hybridoma and plasmacy-
toma growth factor activities after dialysis against culture medium. Reversed-phase HPLC
was performed on a Cl-column (TSK TMS 250 ; LKB) equilibrated in 0.05% trifluoroacetic
acid (TFA) and eluted at 0.8 ml/min with a gradient of acetonitrile containing 0.05%
TFA. 1-min fractions were collected. Pure IL-HP1 was obtained from crude TUC2 .15
supernatant by sequential gel filtration, anion exchange, and reversed-phase HPLC as
described (11). Upon SDS-PAGE, material prepared according to this procedure is
resolved in multiple bands (Fig. 1), which all display HGF activity. The purity of this
material has been further demonstrated by the finding of a single NH2-terminal amino
acid sequence (11). Semipurified BSF-1 was obtained after gel filtration, anion-exchange
and Cl reversed-phase HPLC as reported (11). This material, which was active on anti-
IgM-stimulated B cells, was found to be free from IL-2 and IL-HP I .
Growth Factor Assays.
￿
Hybridoma growth factor (HGF) titrations were performed by
incubating mouse factor-dependent B cell hybridoma 7TD1 (2,000 cells/microwell) with
serial dilutions of the fractions to be tested in a final volume of 0.2 ml. Cell numbers were
evaluated after 4 d at 37°C by measuring hexosaminidase levels as described (11). A titer
of 1 U/ml was arbitrarily assigned to material that produced half-maximal growth of
hybridoma 7TD 1 . The plasmacytoma growth factor assay was carried out on appropriately
diluted fractions with factor-dependent plasmacytoma cell lines (3,000 cells/microwell).
Cells were incubated in triplicate cultures and pulsed with methyl-[8H]thymidine (0.5
PCi/well) during the last 12 h of a 72-h incubation. For clarity, standard errors, which
did not exceed 10% of the means, are not shown. IL-2 was measured with the CTLL
assay (13).
Results and Discussion
of six plasma cell tumors that failed to grow in vitro in normal primary
cultures, five readily gave rise to vigorous cell lines in the presence of medium
conditioned by helper T cell clone TUC2 .15, which was previously shown to
support the growth of B cell hybridomas (11). In the absence of supernatant, notSilver-stained SDS-PAGE ofpurified IL-HPL Sample wasrunundernonreducing
conditions in a 15% polyacrylamide gel as described by Laemmli (14) and stained according
to Morrissey (15) . Bands at 67 and 59 kD are staining artefacts .
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FIGURE 2 .
￿
Growth curves o£ MOPC 104E and TEPC 1033 in primary cultures. Cultures
were setup either in the absence (O) or in the presence (0) of 2% supernatant of helperT cell
clone TUC2.15 .
643
11 line could be established in this experiment. By extrapol
growth curves (shown in Fig . 2 forMOPC 104E and TEPC 1033) to time 0, the
frequency of cellscapable ofproliferation in primary cultures supplemented with
supernatant could be evaluated for four of the five successfully adapted tumors
(Table 1) . These frequency estimates, which ranged from 0.03 to 0.5, were at
least five orders of magnitude above those of cultures set up in the absence ofT
cell supernatant .
several months in culture, four of the five plasmacytoma cell lines
remained strictly dependenton thecontinuous presence ofTUC2.15 supernatant
in the culture medium . The exception was the MOPC 315 line, which was able
to proliferate, although at a reduced rate, in the absence of supernatant . The644 PLASMACYTOMA GROWTH FACTOR ACTIVITY OF INTERLEUKIN-HPI
TABLE I
Facilitation ofPrimary Cultures ofMouse Plasmacytomas by Supernatant of
Helper T Cell Clone TUC2.15
Culture conditions were as described under Materials and Methods. The
frequency of cells capable of in vitro proliferation was calculated by extrapo-
lating growth curves to time 0.
* Calculated for established cell lines grown in the presence of 2% TUC2.15
supernatant.
four lines that failed to survive without supernatant were used in subsequent
attempts to identify T cell-derived plasmacytoma growth factors.
Screening of a panel of murine helper T cell supernatants showed a strong
correlation between hybridoma and plasmacytoma growth factor titers (n = 12,
r = 0.97 for MOPC 173), suggesting that the same factor could be responsible
for both hybridoma and plasmacytoma growth. This idea was further supported
by the finding that both activities copurified in analytical fractionations of
TUC2.15 supernatant. As illustrated in Fig. 3 for MOPC 173, it was impossible
to separate plasmacytoma growth factor from hybridoma growth factor by either
gel filtration, isoelectric focusing, or reversed-phase HPLC. Identical results
were obtained with MOPC 104E, RPC 20, and TEPC 1033. The heterogeneity
ofthe plasmacytoma and hybridoma growth factor activities in isoelectric focus-
ing was most probably due to variations in glycosylation because it was consid-
erably reduced upon treatment with neuraminidase (results not shown). Collec-
tively, these observations provided strong evidence for the idea that the hybri-
doma growth factor previously identified as IL-HPI (11) represented the major
and probably the only plasmacytoma growth factor present in TUC2.15 super-
natant. Further proof of this hypothesis was obtained with IL-HPI purified to
homogeneity, which, at optimal concentration, induced maximal plasmacytoma
proliferations that were comparable with those induced by crude TUC2.15
supernatant. From the dose-response curves shown in Fig. 4, the concentrations
of IL-HPI required for half-maximal growth of plasmacytomas were evaluated
at approximately 30 pM. Noteworthy, two IL-HPI-dependent hybridomas,
which we have used as indicator cells in the IL-HP1 assay, required 200-fold less
growth factor for half-maximal proliferation than the plasmacytoma lines. Al-
though the significance ofthis difference is presently not clear, it is conceivable
that some complementation occurs in hybridomas, resulting in an abnormally
high sensitivityto IL-HPI. The fact that IL-HPI-independent cells emergemuch
more frequently from IL-HPI-dependent hybridoma lines than from plasmacy-
toma lines (our unpublished observation) seems to support this view.
Plasmacytomas
Frequency of
Without
TUC2.15
proliferating cells
With
TUC2.15
Doubling
time*
h
MOPC 104E <4 x 10-6 2 x 10-' 36
MOPC 173 <4 x 10"6 3 x 10' 20
MOPC 315 <4 x 10-6 3 x 10-2 25
RPC 20 <10-6 ND 25
TEPC 1033 <4 x 10-6 5 x 10' 16
FLOPC 21 <4 x 10-6 <4 x 10-6 -VAN SNICK ET AL .
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FIGURE 3 .
￿
Copurification of hybridoma and plasmacytoma growth factors . Fractions were
titrated for hybridoma growth factor (stippled area) and tested at a selected dilution for
plasmacytoma growth factor . In the absence of supernatant, ['H]thymidine incorporation
levels ofplasmacytoma MOPC 173 amounted to about 350 cpm. (A) Gel filtration on Ultrogel
AcA 54 . The plasmacytoma growth factor assay was performed on fractions diluted 10,000-
fold . (B) Isoelectric focusing. Proliferation of the MOPC 173 line was tested in the presence
of fractions diluted 1,000-fold . (C) Reversed-phase HPLC on a Cl-column. Plasmacytoma
growth factor was assayed on fractions diluted 10,000-fold.
Three IL-HP1-dependent plasmacytoma cell lines(MOPC 104E,RPC 20, and
TEPC 1033) that hadbeen maintained in culture for several months were tested
for tumorigenicity in pristane-treated, irradiated (500 rad) BALB/c mice . After646 PLASMACYTOMA GROWTH FACTOR ACTIVITY OF INTERLEUKIN-HP1
E 105
a
z 0
a a 104
a
z
0 u z
z 103
0 s
r
x
H C
1
￿
5
￿
25
￿
125 625 3125
￿
1
￿
5
￿
25 125 625 3125
￿
1
￿
5
￿
25 125 625 3125
GROWTH FACTOR DILUTIONS
FIGURE 4.
￿
Comparison of plasmacytoma growth factor activity of crude TUC2.15 superna-
tant andof purified IL-HP1 . Plasmacytoma cell lines(A, MOPC 104E; B, MOPC 173; C, RPC
20) established and maintained in vitro in the presence of 2% TUC2.15 supernatant were
washed free ofT cell factorsandincubated with decreasing concentrations of crudeTUC2.15
supernatant (9) or of purified IL-HP1 (O). Proliferation in the absence of growth factors is
represented by (X). Initial concentration of TUC2.15 supernatant was 10% (vol/vol) and that
of purified IL-HP1 was estimatedat about 2 nM on the basis ofsilver-stained gels.
i.p. injection of 5 X 105 cells, the three lines were found to form tumors that
killed the animals in less than 2 wk, indicating that IL-HP1-dependent plasma-
cytomas are still able to proliferate in vivo. Whether this means that these cells
do not need IL-HP1 in vivo or that there is enough IL-HP1 or related molecules
in the peritoneal cavity ofpristane-treated mice is not known.
Another problem that remains to be solved is that ofthe specificity ofIL-HP1
for cells ofthe B cell lineage. The importance ofthis question is highlighted by
the recent finding that BSF-1, a lymphokine formerly thought of as a B cell-
specific factor, has now been found to stimulate the proliferation of certain T
cell lines (16, 17). As a first step in the analysis of the specificity of IL-HP1, we
therefore compared the effects of IL-2, BSF-1, and IL-HP1 on the proliferation
of IL-2-dependent cytolytic T cell line (CTLL), helper T cell clone TUC2.15,
and plasmacytoma TEPC1033. As shown in Table 11, TUC2.15 cells, which
responded very well to BSF-1 and to IL-2, failed to proliferate in the presence
of IL-HP1 even at a concentration in 100-fold excess of that required by
plasmacytomas. Similar results were obtained with several other helper T cell
clones. Although these results do not prove that IL-HP1 is a B cell-specific
growth factor, they clearly show thatthis molecule does not stimulate the growth
of every established cell line. Moreover, the data in Table II also formally
demonstrate the functional difference between BSF-1 and IL-HP1, which cor-
roboratesthephysicochemical differences already noted between these molecules
(11, 18, 19).
Many different cell types, including macrophages (3, 9, 20), endothelial cells
(21), peripheral blood cells (22), fibroblasts, (23) and Tlymphocytes (11 and this
report), have now been reported to secrete growth factors for hybridomas and
plasmacytomas. It is difficultfor thetime being toevaluate thestructural relations
between these factors because, in most cases, they have not been cloned or
purified to homogeneity. This situation is complicated even further by the fact
that the structural data that are available are related to factors derived from
different species. This is the reason why we do not presently know whether IL-
HP1 is the mouse homologueofthe plasmacytoma growth factor thatwe recently
identified in media conditioned by human fibroblasts, and which appeared to beVAN SNICK ET AL.
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TABLE II
Response ofT Cell- and Plasmacytoma Lines to IL-2, BSF-1, andIL-HPI
['H]Thymidine incorporation by:
CTLL (2 x 10' cells), TUC2.15 (5 x 10' cells) and TEPC1033 (5 x 10' cells) were
incubated in microtiter wells in the presence of the indicated growth factors.
['H]Thymidine was added after24-48h, and incorporation wasmeasured 16 h later.
* 1 U/ml is defined as the titer of a growth factor preparation that stimulates half-
maximal proliferation of the appropriate target cell: CTLL, anti-IgM-stimulated B
cellsand hybridoma7TDI for IL-2, BSF-1, and IL-HPI, respectively.
Human rIL-2 was a gift of Dr. W. Fiers (State University of Ghent, Ghent, Belgium).
identical with a molecule previously described as 26K factor, also known as
interferon a2 (Van Damme, J., G. Opdenakker, A. Billiau, M. Rubina, R.
Simpson, S. Cayphas, A. Vink, and J. Van Snick, manuscript submitted for
publication.
Summary
We have recently described the purification and NH2-terminal amino acid
sequence of a T cell-derived hybridoma growth factor that was provisionally
designated interleukin-HPI (IL-HPI). Here we report that a T cell supernatant
containing high titers of this hybridoma growth factor considerably facilitated
the establishment of primary cultures of murine plasmacytomas. Most plasma-
cytoma cell lines derived from such cultures remained permanently dependent
on IL-HPI-containing T cell supernatant for both survival and growth in vitro.
These cell lines, however, retained their ability to form tumors in irradiated
pristane-treated mice.
Analytical fractionation of a T cell supernatant rich in IL-HPI by either gel
filtration, isoelectric focusing, or reversed-phase HPLC revealed the existence
of only one plasmacytoma growth factor activity that strictly copurified with IL-
HP1, strongly suggesting the identity ofboth factors. This conclusion was further
supported by the finding that IL-HPI purified to homogeneity supported the
Growth factors Dose*
U/ml
T cell
CTLL
lines
Tuc2.15
cpm
Plasmacy-
toma line
TEPC1033
None - 173 145 94
rIL-2$ 20 79,695 155,950 57
4 78,397 142,530 52
0.8 30,480 41,318 69
0.16 9,293 1,011 51
BSF-1 125 96 107,103 490
25 103 45,907 323
5 139 3,717 93
1 127 138 60
IL-HPI 10,000 146 262 34,300
2,000 124 243 46,200
400 155 346 28,600
80 107 170 7,900648 PLASMACYTOMA GROWTH FACTOR ACTIVITY OF INTERLEUKIN-HP 1
growth ofboth B cell hybridomas and plasmacytomas. For half-maximal growth,
plasmacytomas, however, required a concentration of IL-HP1 of^"30 pM, which
is ^200 times higher than that required by B cell hybridomas.
A clear difference in the specificity ofIL-HP1 and B cell stimulatory factor 1
(BSF-1) was demonstrated by the findingthat IL-HP1-dependent plasmacytomas
did not survive in the presence of BSF-1, whereas helper T cell lines that
proliferated in the presence of BSF-1 failed to respond to IL-HP1.
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